Effector Therapeutics company info

What does Effector Therapeutics do?
Effector Therapeutics (NASDAQ:EFTR) is a Nasdaq-listed biotech company pioneering a new weapon against cancer: selective translation regulator inhibitors (STRIs). These drugs target specific proteins crucial for tumor growth, potentially offering a more precise approach than traditional chemotherapy. Despite a recent setback in a non-small cell lung cancer (NSCLC) trial, Effector presses on. Their pipeline explores STRIs for various cancers, with ongoing development efforts. While the future hinges on clinical trial success, Effector's innovative approach positions them as a player to watch in the oncology space.
Effector Therapeutics company media
Company Snapshot

Is Effector Therapeutics a public or private company?


How many people does Effector Therapeutics employ?


What sector is Effector Therapeutics in?

pie chart
Health Care

Where is the head office for Effector Therapeutics?

location pin
Head Office
California, United States

What year was Effector Therapeutics founded?

founded flag
Year Founded
What does Effector Therapeutics specialise in?
/Cancer Therapeutics /Drug Discovery /Clinical Development /Molecular Medicine /Gene Expression /Tumor Treatment

What are the products and/or services of Effector Therapeutics?

Overview of Effector Therapeutics offerings
Selective Translation Regulator Inhibitors (STRIs): This is the core product category. STRIs are a new class of drugs being developed by Effector to target specific proteins involved in cancer cell growth and proliferation.
STRI for Non-Small Cell Lung Cancer (NSCLC): This is a specific type of STRI being developed to treat NSCLC, a common form of lung cancer. (Note: Development for this specific use case might be on hold after a recent setback in trials).
STRIs for Other Cancers: Effector's pipeline likely includes STRIs targeting other cancer types beyond NSCLC. However, specifics might not be publicly disclosed yet.
Pre-Clinical and Clinical Trial Programs: These are the development stages for their STRI drugs. Pre-clinical trials involve testing in cells or animals, while clinical trials involve testing in human subjects.
Collaboration with Research Institutions: Effector might collaborate with universities or research institutions to develop and test their STRI therapies.
Licensing Agreements (Potentially): In the future, Effector might license their STRI technology or drugs to other pharmaceutical companies for broader development and commercialization.

Who is in the executive team of Effector Therapeutics?

Effector Therapeutics leadership team
  • Dr. Stephen T. Worland Ph.D.
    Dr. Stephen T. Worland Ph.D.
    CEO, President & Director
  • Mr. Michael  Byrnes M.B.A.
    Mr. Michael Byrnes M.B.A.
    Chief Financial Officer
  • Dr. Douglas  Warner M.D.
    Dr. Douglas Warner M.D.
    Chief Medical Officer
  • Dr. Davide  Ruggero Ph.D.
    Dr. Davide Ruggero Ph.D.
    Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Kevan M. Shokat Ph.D.
    Dr. Kevan M. Shokat Ph.D.
    Co-Founder and Member of Clinical & Scientific Advisory Board